HVTN 324

Recruiting
99 years or below
All
Phase N/A
10 participants needed
1 Location

Brief description of study

To assess the safety and tolerability of 2 dose levels of DV901-NP at months 0 and 2, followed by DV902-NP booster at months 4 and 6, both admixed with ACU-026-001-1 adjuvant for Groups 1 and 2 (Prime Boost Cohort); to assess the safety and tolerability of 1 dose level of DV901-NP at months 0 and 2, followed by CH505 TF mRNA-gp160 at month 4 and 6, and CH505 w24 mRNA-gp160 at month 8 for Group 3 (Prime Boost Cohort); to assess the safety and tolerability of 1 dose level of DV901-NP at months 0, 1, and 7 for Groups 4 and 5 (Immunology Cohort), admixed with ACU-026-001-1 adjuvant.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 25 Aug 2026. Study ID: 26-7608

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center